Schroder Investment Management Group Sells 42,750 Shares of Haemonetics Co. (NYSE:HAE)

Schroder Investment Management Group reduced its position in Haemonetics Co. (NYSE:HAE) by 4.6% in the fourth quarter, Holdings Channel.com reports. The fund owned 894,539 shares of the medical instruments supplier’s stock after selling 42,750 shares during the period. Schroder Investment Management Group’s holdings in Haemonetics were worth $69,846,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Pictet Asset Management Holding SA boosted its holdings in shares of Haemonetics by 16.4% during the 4th quarter. Pictet Asset Management Holding SA now owns 6,963 shares of the medical instruments supplier’s stock valued at $544,000 after acquiring an additional 979 shares during the last quarter. Norges Bank purchased a new stake in Haemonetics in the fourth quarter worth approximately $32,803,000. Zions Bancorporation N.A. grew its position in Haemonetics by 56.3% in the 4th quarter. Zions Bancorporation N.A. now owns 40,996 shares of the medical instruments supplier’s stock worth $3,201,000 after purchasing an additional 14,762 shares during the period. KLP Kapitalforvaltning AS purchased a new stake in Haemonetics during the 4th quarter valued at $789,000. Finally, Quantbot Technologies LP bought a new position in shares of Haemonetics during the 4th quarter valued at $345,000. 99.67% of the stock is owned by institutional investors.

Analysts Set New Price Targets

Several analysts recently commented on HAE shares. Bank of America lowered Haemonetics from a “neutral” rating to an “underperform” rating and cut their price objective for the stock from $95.00 to $68.00 in a report on Friday, February 7th. Needham & Company LLC cut their price target on Haemonetics from $108.00 to $104.00 and set a “buy” rating for the company in a research note on Tuesday, March 18th. Barrington Research reduced their price target on shares of Haemonetics from $108.00 to $95.00 and set an “outperform” rating for the company in a research report on Friday, February 7th. JPMorgan Chase & Co. initiated coverage on shares of Haemonetics in a report on Friday, December 6th. They issued an “overweight” rating and a $116.00 price objective on the stock. Finally, Raymond James reaffirmed a “strong-buy” rating and set a $115.00 target price (down from $120.00) on shares of Haemonetics in a report on Friday, February 7th. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating, six have given a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $101.22.

Haemonetics Price Performance

NYSE HAE opened at $63.65 on Tuesday. The company has a current ratio of 3.97, a quick ratio of 2.55 and a debt-to-equity ratio of 1.35. Haemonetics Co. has a 12 month low of $58.80 and a 12 month high of $97.97. The stock has a market cap of $3.20 billion, a price-to-earnings ratio of 25.06, a PEG ratio of 1.11 and a beta of 0.43. The company’s 50 day moving average is $65.85 and its two-hundred day moving average is $74.63.

Haemonetics (NYSE:HAE) last announced its quarterly earnings data on Thursday, February 6th. The medical instruments supplier reported $1.19 EPS for the quarter, missing the consensus estimate of $1.20 by ($0.01). Haemonetics had a net margin of 9.47% and a return on equity of 23.66%. As a group, research analysts anticipate that Haemonetics Co. will post 4.55 earnings per share for the current year.

About Haemonetics

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app.